Page last updated: 2024-11-12

tixocortol pivalate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tixocortol pivalate: used in drug therapy of allergic rhinitis, structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tixocortol pivalate : The pivalate thioester of tixocortol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID15052414
CHEMBL ID2107112
CHEBI ID63564
SCHEMBL ID6827
MeSH IDM0071279

Synonyms (38)

Synonym
55560-96-8
tixocortol pivalate (usan)
D06171
tixocortol pivalate [usan]
11beta,17-dihydroxy-21-mercaptopregn-4-ene-3,20-dione 21-pivalate
einecs 259-706-4
jo-1016
s-(11beta,17-dihydroxypregn-4-ene-3,20-dione) 21-(thiopivalate)
jo 1016
tixocortol 21-pivalate
pregn-4-ene-3,20-dione, 21-((2,2-dimethyl-1-oxopropyl)thio)-11,17-dihydroxy-, (11beta)-
pivalone
tixocortol pivalate
CHEMBL2107112
tixocortol-21-pivalate
unii-6k28e35m3b
6k28e35m3b ,
s-(11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl) 2,2-dimethylpropanethioate
CHEBI:63564 ,
(11beta)-11,17-dihydroxy-21-((2,2-dimethyl-1-oxopropyl)thio)pregn-4-ene-3,20-dione
EPITOPE ID:161747
tixocortol pivalate [vandf]
tixocortol pivalate [who-dd]
pregn-4-ene-3,20-dione, 21-((2,2-dimethyl-1-oxopropyl)thio)-11,17-dihydroxy-, (11.beta.)-
tixocortol 21-pivalate [mi]
tixocortol pivalate [mart.]
SCHEMBL6827
s-[11beta,17-dihydroxypregn-4-ene-3,20-dione] 21-(thiopivalate)
s-(2-((8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) 2,2-dimethylpropanethioate
Q7810487
DTXSID30970904
s-(11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl) 2,2-dimethylpropanethioate
jo1016
s-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanethioate
(11beta)-21-[(2,2-dimethyl-1-oxopropyl)thio]-11,17-dihydroxypregn-4-ene-3,20-dione
AKOS040746414
CS-0107519
HY-130365

Research Excerpts

Overview

Tixocortol pivalate is a corticosteroid with topical anti-inflammatory activity equal to that of hydrocortisone. It was shown to be a sensitizer in the guinea pig, but cross-reactions to other tests were not observed.

ExcerptReferenceRelevance
"Tixocortol pivalate (TP) is a good marker for hydrocortisone allergy. "( Tixocortol pivalate: what is the right concentration?
English, JS; Gawkrodger, D; Green, CM; Horne, H; Kalavala, M; King, C; Ormerod, AD; Sansom, J; Statham, BN; Wilkinson, MS, 2007
)
3.23
"Tixocortol pivalate is a corticosteroid with topical anti-inflammatory activity equal to that of hydrocortisone. "( Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application.
Bolte, E; Du Souich, P; Goyer, R; Larochelle, P; Lelorier, J, 1983
)
3.15
"Tixocortol pivalate was shown to be a sensitizer in the guinea pig, but cross-reactions to other tested corticosteroids were not observed."( Sensitization studies with mometasone furoate, tixocortol pivalate, and budesonide in the guinea pig.
Bjorkner, B; Bruze, M; Dooms-Goossens, A, 1996
)
1.27
"Tixocortol pivalate is an established marker to topical corticosteroid allergy. "( Contact hypersensitivity to tixocortol pivalate.
el-Azhary, RA; Fransway, AF; Gibson, LE; Lutz, ME, 1998
)
2.04
"Tixocortol pivalate is a steroid reportedly without significant adrenal-pituitary axis suppression when administered via the gastrointestinal tract. "( Effects of tixocortol pivalate on gastrointestinal disease in systemic mastocytosis: a preliminary study.
Friedman, BS; Metcalfe, DD, 1991
)
2.11

Effects

ExcerptReferenceRelevance
"Tixocortol pivalate has been incorporated in our standard 1-52 patch test series since November 1992. "( Contact hypersensitivity to tixocortol pivalate.
el-Azhary, RA; Fransway, AF; Gibson, LE; Lutz, ME, 1998
)
2.04

Treatment

ExcerptReferenceRelevance
"Pretreatment with tixocortol pivalate stimulated the initial phagocytosis of C."( A comparison of the effects of tixocortol pivalate (JO 1016), hydrocortisone acetate and beclomethasone dipropionate on the phagocytosis and lysis of microorganisms by alveolar macrophages.
Poole, A; Uphill, PF, 1981
)
0.87

Pharmacokinetics

ExcerptReferenceRelevance
"Comparative pharmacokinetic studies of [14C]tixocortol pivalate ([14C]TP) and [14C]cortisol were carried out in rats."( Comparative pharmacokinetic studies of tixocortol pivalate and cortisol in the rat.
Chanoine, F; Junien, JL, 1984
)
0.8

Dosage Studied

ExcerptRelevanceReference
" Specific procedures of preparation and dosage remain to be established."( New enema treatments for inflammatory bowel disease.
Karp, LC; Targan, SR, 1988
)
0.27
" It was evaluated in a group of 18 normal subjects to determine whether it exerted any systemic glucocorticoid activity after single oral or intrarectal doses and after short-term dosing by the intranasal route."( Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application.
Bolte, E; Du Souich, P; Goyer, R; Larochelle, P; Lelorier, J, 1983
)
1.71
" A multiple dose guinea pig maximization test (GPMT) was therefore used to study the dose-response relationship of tixocortol pivalate."( Tixocortol pivalate contact allergy in the GPMT: frequency and cross-reactivity.
Andersen, KE; Frankild, S; Kreilgaard, B; Lepoittevin, JP, 2001
)
1.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
anti-allergic agentA drug used to treat allergic reactions.
glucocorticoid receptor agonistAn agonist that selectively binds to and activates a glucocorticoid receptor.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
corticosteroidA natural or synthetic analogue of the hormones secreted by the adrenal gland.
thioesterA compound of general formula RC(=O)SR'. Compare with thionoester, RC(=S)OR'.
pivalate esterA carboxylic ester of pivalic acid.
tertiary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (35.29)18.7374
1990's34 (40.00)18.2507
2000's14 (16.47)29.6817
2010's7 (8.24)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.42 (24.57)
Research Supply Index4.62 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index77.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (9.89%)5.53%
Reviews4 (4.40%)6.00%
Case Studies18 (19.78%)4.05%
Observational0 (0.00%)0.25%
Other60 (65.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]